Search Results
Oct 20, 2025, 01:44 ET Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
cell-mediated cytotoxicity (ADCC) activity. Based on the results of a multi-center, randomized, open-label, controlled, Phase 3 KL166-III-06 study, trastuzumab botidotin was approved for marketing by the NMPA in for adult patients with unresectable or metastatic HER2 positive BC
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 19, 2025, 22:01 ET Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 18, 2025, 10:42 ET Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 17, 2025, 10:00 ET Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
CD44v9 binding affinity, a hydrolysable linker, and a belotecan derivative payload (a novel and clinically validated topoisomerase-1 inhibitor, named KL610023, collaborating with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK)). CD44v9 is involved in broad biological pathways and has an implicated
More news about: Multitude Therapeutics, Inc.
Oct 17, 2025, 05:42 ET Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC
The approval is based on a multi-center, randomized, open-label, controlled, Phase 3 KL166-III-06 study that evaluates the efficacy and safety profile of trastuzumab botidotin versus T-DM1 in patients with HER2-positive unresectable or metastatic
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 16, 2025, 08:00 ET Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston
development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's disease,
More news about: Klotho Neurosciences, Inc.
Oct 09, 2025, 09:00 ET UST Expands Core Banking Capabilities with the Acquisition of Modus Information Systems
platform and hosting services, and system integration. Together, we will deliver greater innovation, agility, and measurable business outcomes," said KL Mohan Kumar, Chief Executive Officer, Modus. "India and the rest of the Global South have experienced rapid economic growth
More news about: UST
Oct 09, 2025, 02:00 ET UST Expands Core Banking Capabilities with the Acquisition of Modus Information Systems
platform and hosting services, and system integration. Together, we will deliver greater innovation, agility, and measurable business outcomes," said KL Mohan Kumar, Chief Executive Officer, Modus. "India and the rest of the Global South have experienced rapid economic growth
More news about: UST
Oct 07, 2025, 18:20 ET Klotho Neurosciences Announces Expiration of Letter of Intent
development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's disease,
More news about: Klotho Neurosciences, Inc.
Sep 30, 2025, 08:30 ET Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership
development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's disease,
More news about: Klotho Neurosciences, Inc.
Sep 25, 2025, 13:25 ET BMC Medical visar upp innovationer inom sömn- och andningsvård på ERS 2025-kongressen i Amsterdam
Future of CPAP Monitoring: What Needs to Change Today" (Framtiden för CPAP-övervakning: Vad behöver förändras idag?)Tisdagen den 15 september, kl. 14.00–14.45 | Rum E103–104 Vid seminariet medverkar ledande experter, bland andra: Dr Renata Riha
More news about: BMC Medical Co., Ltd.
Sep 24, 2025, 12:43 ET BMC Medical præsenterer innovationer inden for søvn- og respirationsbehandlings på ERS 2025 i Amsterdam
være vært for en sponsoreret workshop ved navn:"The Future of CPAP Monitoring: What Needs to Change Today?"Tirsdag den 15. september kl. 14.00-14.45 | Lokale E103-104 Førende eksperter deltager i workshoppen, herunder: Dr. Renata Riha
More news about: BMC Medical Co., Ltd.
Sep 24, 2025, 12:41 ET BMC Medical viser frem innovasjoner innen søvn- og respirasjonsbehandling på ERS 2025 i Amsterdam
til utstillingen vil BMC arrangere en sponset workshop:«Fremtiden innen CPAP-overvåking: Hva må endres i dag?»Tirsdag 15. september, kl. 14:00-14:45 | Rom E103–104 Økten vil ha ledende eksperter, inkludert: Dr. Renata Riha (
More news about: BMC Medical Co., Ltd.
Sep 23, 2025, 04:57 ET Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sep 22, 2025, 22:16 ET Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC
metastatic non-small cell lung cancer (NSCLC). This acceptance for review is based on the positive results from the two pivotal Phase 2 cohorts of the KL400-I/II-01 study for both 1L and 2L+ advanced RET-fusion positive NSCLC.
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sep 16, 2025, 03:00 ET Nu åbent: 1 Hotel Copenhagen - Et naturinspireret nordisk flagskib
løbeklub og meget mere. I baren, PÆRE, er der live musikoptrædener, og hver fredag og lørdag forvandles baren til et socialt samlingspunkt med DJs fra kl. 19 til 23. Hotellet er familievenligt med aktiviteter, der vækker børns nysgerrighed for naturen og styrker deres relation til miljøet. Hunde
More news about: Starwood Hotels